Our total project portfolio consists of seven drug development projects, of which four projects are prepared for phase IIa or phase IIb. What the projects have in common is that they are based on two unique validated technology platforms that are based on solid research and collaborations with pioneering and internationally recognized researchers and academics.
The cPLA2α technology consists of a series of proprietary small molecule inhibitors of the cytosolic phospholipase A2 (cPLA2α) enzyme involved in inflammation and uncontrolled cell growth. This provides a range of potentially attractive indications for the patented molecular inhibitors of cPLA2α including skin, cancer, liver and kidney diseases.
The technology comes primarily from the Norwegian University of Science and Technology (NTNU).
The development projects of the portfolio companies Avexxin Oncology AS and Reccura Therapeutics AS are based on this technology.
The FOL peptide technology consists of a series of patented tissue-protective peptides ("small proteins") that are based on a modified part of the natural human protein osteopontin. Osteopontin is a glycoprotein expressed in many types of tissues, including the hair follicle and bone, and plays a key role in cell stimulation processes.
The technology comes primarily from Lund University in Sweden.
The development projects of the portfolio company Follicum AB are based on this technology.
Stimulation of hair growth
FOL005 is a peptide based on a modified part of the endogenous osteopontin, a glycoprotein expressed by many tissues.FOL005 has shown to be a potent and safe drug candidate for stimulation of hair growth.
FOL005 is a peptide based on a modified part of the endogenous osteopontin, a glycoprotein expressed by many tissues. FOL005 has promising anti-fibrotic, revascularization and angiogenic properties which means that FOL005 also has an interesting therapeutic potential in treating the healing process in wounds.
AVX001 is one of our drug candidates built on the cPLA2α platform. It is an inhibitor for topical administration that we are developing for the indications actinic keratosis (AK) and basal cell carcinoma (BCC). AVX001 has shown "Proof of concept" in our latest phase lla study for AK.
AVX420 has a documented strong cPLA2α inhibitory effect in leukemia and triple-negative breast cancer, which shows that AVX420 may be a promising drug candidate for treatment of several types of cancer.
Kidney and liver fibrosis
AVX420 and FOL026 have proven their therapeutic potential for the treatment of fibrosis, for example in chronic kidney disease or liver disease.
FOL056 is a peptide-based drug candidate with novel and promising properties as potential innovative therapies in cardiovascular disease associated with diabetes.